Literature DB >> 12845489

In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats.

Markus Mitterhauser1, Wolfgang Wadsak, Leila Wabnegger, Werner Sieghart, Helmut Viernstein, Kurt Kletter, Robert Dudczak.   

Abstract

11beta-Hydroxylase (CYP11B1, P45011beta) plays an important role in the biosynthesis of cortisol and aldosterone and has been shown to be a good target for the in vivo imaging of adrenocortical incidentalomas in nuclear medicine. [11C]Metomidate (MTO), a potent inhibitor of this enzyme, is used for positron emission tomography (PET) imaging of adrenocortical pathology. The synthesis of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid 2-[18F]fluoroethylester (FETO), a close analogue to MTO and etomidate (ETO), has been presented recently, and the present investigation aimed to characterise the in vivo distribution of FETO. Since ETO is a well-known anaesthetic drug acting via the GABAergic system, the interaction of FETO with GABAA receptors was also evaluated. Eighteen male Sprague-Dawley rats were injected with 1.73-3.06 MBq of FETO into a tail vein after venodilatation in a 40 degrees C water bath. Rats were sacrificed by exsanguination from the abdominal aorta under deep ether anaesthesia after 10 (n=6), 30 (n=6) or 60 min (n=6); organs were removed, weighed and counted. For binding experiments, rat cerebellar membranes were incubated for 90 min at 4 degrees C in TC-50 buffer, 150 mM NaCl and 2 nM of [3H]flunitrazepam in the absence or presence of 10 microM diazepam or various concentrations of ETO, MTO and FETO. In vivo evaluation evinced very high uptake in the adrenal glands (7.52%+/-1.19% ID/g at 30 min), followed by lung (1.18%+/-0.19% ID/g, 10 min), liver (0.59%+/-0.13% ID/g, 10 min) and duodenum (0.7%+/-0.29% ID/g, 60 min). No defluorination nor fluoroethyl-ester cleavage was observed. When brain regions were compared with the thalamus (the reference region), highest relative uptake was seen in the cortex (2.34), followed by "rest brain" (2.13) and cerebellum (1.96). FETO and ETO were able to increase the binding of [3H]flunitrazepam with similar potencies and to a comparable extent. It is concluded that FETO shows characteristics suitable for the imaging of adrenocortical pathology with PET. Binding experiments on GABA receptors demonstrate a comparable effect of FETO and ETO. Hence, FETO possibly could also be used to elucidate the function, dynamics and kinetics of narcotic drugs with PET.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845489     DOI: 10.1007/s00259-003-1252-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  6 in total

1.  PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate.

Authors:  M Bergström; C Juhlin; T A Bonasera; A Sundin; J Rastad; G Akerström; B Långström
Journal:  J Nucl Med       Date:  2000-02       Impact factor: 10.057

Review 2.  Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.

Authors:  W Sieghart
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

3.  Quantification of P450scc, P450(17) alpha, and iron sulfur protein reductase in Leydig cells and adrenals of inbred strains of mice.

Authors:  L M Perkins; A H Payne
Journal:  Endocrinology       Date:  1988-12       Impact factor: 4.736

4.  Effect of chronic (-)-nicotine treatment on rat cerebral benzodiazepine receptors.

Authors:  Y Magata; H Kitano; T Shiozaki; Y Iida; S Nishizawa; H Saji; J Konishi
Journal:  Nucl Med Biol       Date:  2000-01       Impact factor: 2.408

5.  In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors.

Authors:  M Bergström; T A Bonasera; L Lu; E Bergström; C Backlin; C Juhlin; B Långström
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

6.  Allosteric modulation of [3H]flunitrazepam binding to recombinant GABAA receptors.

Authors:  A Slany; J Zezula; K Fuchs; W Sieghart
Journal:  Eur J Pharmacol       Date:  1995-10-15       Impact factor: 4.432

  6 in total
  7 in total

1.  [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers.

Authors:  Wolfgang Wadsak; Markus Mitterhauser; Gundula Rendl; Matthias Schuetz; Leonhard Key Mien; Dagmar E Ettlinger; Robert Dudczak; Kurt Kletter; Georgios Karanikas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

2.  Radiosynthesis of [124I]iodometomidate and biological evaluation using small-animal PET.

Authors:  Herbert Kvaternik; Thomas Wanek; Friedrich Hammerschmidt; Ilse Zolle; Reingard Aigner; Claudia Kuntner
Journal:  Mol Imaging Biol       Date:  2014-06       Impact factor: 3.488

3.  [18F]FETO: metabolic considerations.

Authors:  Dagmar E Ettlinger; Wolfgang Wadsak; Leonhard-Key Mien; Michael Machek; Leila Wabnegger; Gundula Rendl; Georgios Karanikas; Helmut Viernstein; Kurt Kletter; Robert Dudczak; Markus Mitterhauser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-11       Impact factor: 9.236

Review 4.  Metomidate-based imaging of adrenal masses.

Authors:  S Hahner; A Sundin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

5.  Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.

Authors:  Georg Zettinig; Markus Mitterhauser; Wolfgang Wadsak; Alexander Becherer; Christian Pirich; Heinrich Vierhapper; Bruno Niederle; Robert Dudczak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

Review 6.  Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT.

Authors:  Iosif A Mendichovszky; Andrew S Powlson; Roido Manavaki; Franklin I Aigbirhio; Heok Cheow; John R Buscombe; Mark Gurnell; Fiona J Gilbert
Journal:  Diagnostics (Basel)       Date:  2016-11-18

7.  Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience.

Authors:  Britta Heinze; Andreas Schirbel; Lukas Nannen; David Michelmann; Philipp E Hartrampf; Christina Bluemel; Magdalena Schneider; Ken Herrmann; Heribert Haenscheid; Martin Fassnacht; Andreas K Buck; Stefanie Hahner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.